Carboprost Tromethamine Global Market Report 2024

The carboprost tromethamine market size has grown strongly in recent years. It will grow from $1.55 billion in 2023 to $1.64 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to rising maternal mortality rates, availability of government funding for maternal health programs, increasing incidence of postpartum hemorrhage, growing awareness about maternal health, and increasing number of gynecological procedures.

The carboprost tromethamine market size is expected to see strong growth in the next few years. It will grow to $2.09 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated expansion during the forecast period can be credited to several factors, including the increasing need for efficient treatments for postpartum hemorrhage, governmental efforts to enhance maternal healthcare, rising healthcare expenditure in developing nations, heightened awareness regarding the advantages of Carboprost Tromethamine, and enhanced regulatory backing for maternal health medications. Key trends projected for the forecast period encompass the uptake of combination therapies to enhance outcomes, heightened emphasis on minimally invasive surgical approaches, innovation in new formulations to enhance efficacy, growing collaborations between pharmaceutical firms and healthcare providers, and an increase in clinical trials exploring novel therapeutic uses.

The increasing focus on maternal health initiatives is anticipated to drive the expansion of the carboprost tromethamine market in the future. Maternal health initiatives aim to enhance the health and well-being of mothers throughout the stages of pregnancy, childbirth, and postpartum, employing targeted interventions and programs. The escalation in maternal health initiatives can be attributed to heightened awareness of maternal health issues, advocacy endeavors, policy modifications, and global endeavors aimed at diminishing maternal mortality rates and enhancing access to maternal healthcare services. These initiatives play a crucial role in promoting the utilization of carboprost tromethamine for effectively managing postpartum hemorrhage. These programs ensure adequate training and accessibility, improve maternal care standards, and reduce mortality rates. For example, as per statistics published by the Kaiser Family Foundation (KFF), a US-based non-profit organization, funding for Maternal and Child Health (MCH) in the U.S. has steadily increased, rising from $1.241 billion in 2021 to $1.277 billion in 2022, and further to $1.302 billion in 2023. Consequently, the surge in maternal health initiatives is propelling the growth of the carboprost tromethamine market.

Major players within the carboprost tromethamine market are increasingly directing their efforts towards the development of single-dose injections of carboprost tromethamine, aiming to enhance patient convenience, ensure accurate dosing, and elevate overall treatment efficacy. These single-dose injections of carboprost tromethamine are administered as a complete dose, providing immediate and sustained therapeutic effects to effectively manage postpartum hemorrhage and control excessive bleeding. For instance, in May 2023, Eugia Pharma Specialties Limited, an India-based pharmaceutical company, obtained approval from the United States Food and Drug Administration (USFDA) for Carboprost Tromethamine Injection USP 250 mcg/mL, Single-Dose Vials. This approval enables Eugia Pharma to produce and market this product, which is indicated for terminating pregnancies between the 13th and 20th weeks of gestation, as well as for treating postpartum hemorrhage resulting from uterine atony.

In November 2021, Amneal Pharmaceuticals, a US-based company specializing in both generic and specialty pharmaceuticals, completed the acquisition of Puniska Healthcare Pvt. Ltd. for a total of $0.084 billion. This acquisition substantially strengthens Amneal's injectable manufacturing infrastructure, as well as its capabilities and capacity, thereby facilitating support for the US market and laying the groundwork for expansion into international markets. Puniska Healthcare Pvt. Ltd., headquartered in India, is a manufacturer of parenteral and injectable medications, including carboprost tromethamine injections.

Major companies operating in the carboprost tromethamine market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Sandoz Inc., Zoetis Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Ferring Holding SA, Woodward Pharma, Amneal Pharmaceuticals Inc., Bio-Techne Corporation, Upsher-Smith Laboratories LLC, West-Ward Pharmaceuticals Corp., Taj Pharmaceuticals Limited, JHP Pharmaceuticals LLC, ANGUS Chemical Company, Biosynth Limited, Universal Biosensors Inc., SimSon Pharma Limited, ChemScene LLC, Ryvis Pharma.

North America was the largest region in the carboprost tromethamine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carboprost tromethamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the carboprost tromethamine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Carboprost tromethamine, employed in obstetric care, is predominantly utilized to manage postpartum hemorrhage and initiate second-trimester abortions. Its capacity to provoke robust uterine contractions makes it a potent intervention for addressing intense bleeding and facilitating medical terminations of pregnancy. Its therapeutic properties include uterotonic effects, rendering it a valuable asset in obstetric and gynecological contexts for managing various conditions.

Carboprost tromethamine is available in two primary forms, injection and tablet. The injection form entails administering the medication through a needle into the muscle. These products are distributed through multiple channels including hospital pharmacies, retail pharmacies, and online pharmacies. They find application in various medical scenarios such as hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis and uterine fibroids, menopause, and polycystic ovary syndrome (PCOS).

The carboprost tromethamine market research report is one of a series of new reports that provides carboprost tromethamine market statistics, including carboprost tromethamine industry global market size, regional shares, competitors with a carboprost tromethamine market share, detailed carboprost tromethamine market segments, market trends and opportunities, and any further data you may need to thrive in the carboprost tromethamine industry. This carboprost tromethamine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The carboprost tromethamine market consists of sales of transdermal patches, nasal spray formulations, vaginal suppositories, and intrauterine devices (IUDs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.